Home-based transcutaneous tibial nerve stimulation for overactive bladder syndrome: a randomized, controlled study

Robert Cava, Yaacov Orlin, Robert Cava, Yaacov Orlin

Abstract

Purpose: Transcutaneous posterior tibial nerve stimulation (TPTNS) for the treatment of overactive bladder syndrome (OAB), with or without urge urinary incontinence (UUI) using electrodes imbedded in the fabric of a conventional sock and an attachable battery-operated stimulation device (ZIDA®-Exodus Innovations, Sufa, Israel), was compared for effectiveness and safety to a sham procedure in a prospective, blinded, randomized, controlled trial.

Methods: Forty patients with diagnosed with OAB were recruited from a single site. There were two groups: a treatment group (21 patients, mean age 64), which used an active ZIDA® activation device (ZIDA) and a sham control group (SCG, 19 patients, mean age 72) randomized in a 1:1 ratio. After individual fitting of the sock and face-to-face instruction in the use of the device, patients in both groups self-administered the treatment once weekly for 30 min at home for a duration of 12 weeks. Prior to randomization and in Week 12, patients completed two 3-day bladder diaries and a quality-of-life (QOL) survey. Treatment success was defined as at least a 50% reduction in urgency voids with or without incontinence or at least a 30% reduction in 24-h frequency from baseline to Week 12. The key secondary endpoint was change in QOL from baseline to Week 12.

Results: The success rate for the primary endpoint in the ZIDA group was 80% (n = 16/20) versus 39% (n = 7/18) in the SCG (p = 0.02). For QOL, the least squares mean difference in change from baseline to Week 12 between the ZIDA and sham control arms total score was - 12.7 (95% CI - 20.2 to - 5.1). No significant adverse effects were observed.

Conclusion: TPTNS using the ZIDA home-based stimulation device offers a safe and effective treatment for patients with OAB syndrome and improves QOL.

Trial regestration: TRN: NCT04470765.

Keywords: Incontinence; Overactive; Posterior tibial nerve; Transcutaneous nerve stimulation; Urinary bladder.

Conflict of interest statement

Y. Orlin: consultant physician, advisory board ZIDA Ltd, ZIDA device patent holder. R. Cava: financial stipend as chief investigator.

© 2022. The Author(s), under exclusive licence to Springer Nature B.V.

Figures

Fig. 1
Fig. 1
Placement of electrodes/electronics integrally embedded into fabric
Fig. 2
Fig. 2
The battery-powered device attached to the sock
Fig. 3
Fig. 3
Summary of allocation, randomization, and intervention

References

    1. Kinsey D, Pretorius S, Glover L, Alexander T. The psychological impact of overactive bladder: a systematic review. J Health Psychol. 2016;21(1):69–81. doi: 10.1177/1359105314522084.
    1. Vaughan CP, Johnson TM, 2nd, Ala-Lipasti MA, Cartwright R, Tammela TL, Taari K, Auvinen A, Tikkinen KA. The prevalence of clinically meaningful overactive bladder: bother and quality of life results from the population based FINNO study. Eur Urol. 2011;59(4):629–636. doi: 10.1016/j.eururo.2011.01.031.
    1. Coyne KS, Sexton CC, Irwin DE, Kopp ZS, Kelleher CJ, Milsom I. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int. 2008;101(11):1388–1395. doi: 10.1111/j.1464-410X.2008.07601.x.
    1. Payne CK. Behavioral therapy for overactive bladder. Urology. 2000;55(5A Suppl):3–16. doi: 10.1016/s0090-4295(99)00484-7.
    1. Magowan BA, Owen P, Thomson A. Female urinary incontinence. In: Magowan BA, Owen P, Thomson A, editors. Clinical Obstetrics and Gynaecology. 4. Philadelphia: Elsevier; 2019.
    1. Zinner NR, Koke SC, Viktrup L. Pharmacotherapy for stress urinary incontinence. Drugs. 2004;64:1503–1516. doi: 10.2165/00003495-200464140-00001.
    1. Hsieh PF, Chiu HC, Chen KC, Chang CH, Chou EC. Botulinum toxin A for the treatment of overactive bladder. Toxins. 2016;8(3):59. doi: 10.3390/toxins8030059.
    1. Dmochowski R, Chapple C, Nitti VW, et al. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol. 2010;184(6):2235–2236. doi: 10.1016/j.juro.2010.08.021.
    1. Siddiqui NY, Wu JM, Amundsen CL. Efficacy and adverse events of sacral nerve stimulation for overactive bladder: a systematic review. Neurourol Urodyn. 2010;29(Suppl 1):S18–S23. doi: 10.1002/nau.20786.
    1. Sukhu T, Kennelly MJ, Kurpad R. Sacral neuromodulation in overactive bladder: a review and current perspectives. Res Rep Urol. 2016;8:193–199. doi: 10.2147/RRU.S89544.
    1. de Wall LL, Heesakkers JP. Effectiveness of percutaneous tibial nerve stimulation in the treatment of overactive bladder syndrome. Res Rep Urol. 2017;9:145–157. doi: 10.2147/RRU.S124981.
    1. Peters K, Carrico DJ, Perez-Marrero RA, Khan AU, Wooldridge LS, et al. Randomized trial of percutaneous tibial nerve stimulation versus sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol. 2010;183:1438–1443. doi: 10.1016/j.juro.2009.12.036.
    1. Finazzi-Agrò E, Petta F, Sciobica F, Pasqualetti P, Musco S, Bove P. Percutaneous tibial nerve stimulation effects on detrusor overactivity incontinence are not due to a placebo effect: a randomized, double-blind, placebo controlled trial. J Urol. 2010;184(5):2001–2006. doi: 10.1016/j.juro.2010.06.113.
    1. Yang DY, Zhao LN, Qiu MX. Treatment for overactive bladder: a meta-analysis of transcutaneous tibial nerve stimulation versus percutaneous tibial nerve stimulation. Medicine. 2021;100(20):e25941. doi: 10.1097/MD.0000000000025941.
    1. Ramírez-García I, Blanco-Ratto L, Kauffmann S, Carralero-Martínez A, Sánchez E. Efficacy of transcutaneous stimulation of the posterior tibial nerve compared to percutaneous stimulation in idiopathic overactive bladder syndrome: randomized control trial. Neurourol Urodyn. 2019;38(1):261–268. doi: 10.1002/nau.23843.
    1. Martin-Garcia M, Crampton J. A single-blind, randomized controlled trial to evaluate the effectiveness of transcutaneous tibial nerve stimulation (TTNS) in overactive bladder symptoms in women responders to percutaneous tibial nerve stimulation (PTNS) Physiotherapy. 2019;105(4):469–475. doi: 10.1016/j.physio.2018.12.002.
    1. Maurelli V, Petta F, Carsillo G, Miano R, Lamorte F, Perugia C, Finazzi Agrò E. Che fare se l'elettrostimolazione percutanea del nervo tibiale funziona? Studio pilota sull’elettrostimolazione trans- dermica domiciliare del nervo tibiale [What to do if percutaneous tibial nerve stimulation (PTNS) works? A pilot study on home-based transcutaneous tibial nerve stimulation] Urologia. 2012;79(Suppl 19):86–90. doi: 10.5301/RU.2012.9366.
    1. Bhide AA, Tailor V, Fernando R, Khullar V, Digesu GA. Posterior tibial nerve stimulation for overactive bladder-techniques and efficacy. Int Urogynecol J. 2020;31(5):865–870. doi: 10.1007/s00192-019-04186-3.
    1. Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, Monga A, Petri E, Rizk DE, Sand PK, Schaer GN. An International urogynecological association (IUGA)/International continence society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J. 2010;21(1):5–26. doi: 10.1007/s00192-009-0976-9.
    1. Abrams P, Avery K, Gardener N, Donovan J, ICIQ Advisory Board (2006) The international consultation on incontinence modular questionnaire: . J Urol 175(3 Pt 1):1063–1066. 10.1016/S0022-5347(05)00348-4
    1. Coyne KS, Thompson CL, Lai JS, Sexton CC. An overactive bladder symptom and health-related quality of life short-form: validation of the OAB-q SF. Neurourol Urodyn. 2015;34(3):255–263. doi: 10.1002/nau.22559.
    1. Patidar N, Mittal V, Kumar M, Sureka SK, Arora S, Ansari MS. Transcutaneous posterior tibial nerve stimulation in pediatric overactive bladder: a preliminary report. J Pediatr Urol. 2015;11(6):351.e1–351.e3516. doi: 10.1016/j.jpurol.2015.04.040.
    1. Booth J, Hagen S, McClurg D, Norton C, MacInnes C, Collins B, Donaldson C, Tolson D. A feasibility study of transcutaneous posterior tibial nerve stimulation for bladder and bowel dysfunction in elderly adults in residential care. J Am Med Dir Assoc. 2013;14(4):270–274. doi: 10.1016/j.jamda.2012.10.021.
    1. Manríquez V, Guzmán R, Naser M, Aguilera A, Narvaez S, Castro A, Swift S, Digesu GA. Transcutaneous posterior tibial nerve stimulation versus extended release oxybutynin in overactive bladder patients. a prospective randomized trial. Eur J Obstet Gynecol Reprod Biol. 2016;196:6–10. doi: 10.1016/j.ejogrb.2015.09.020.
    1. de Sèze M, Raibaut P, Gallien P, Even-Schneider A, Denys P, Bonniaud V, Gamé X, Amarenco G. Transcutaneous posterior tibial nerve stimulation for treatment of the overactive bladder syndrome in multiple sclerosis: results of a multicenter prospective study. Neurourol Urodyn. 2011;30(3):306–311. doi: 10.1002/nau.20958.
    1. European Association of Urology (2018) EAU Guidelines on urinary incontinence in adults. Retrieved from . Accessed 27 May 2022
    1. Peters KM, Macdiarmid SA, Wooldridge LS, Leong FC, Shobeiri SA, Rovner ES, Siegel SW, Tate SB, Jarnagin BK, Rosenblatt PL, Feagins BA. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. J Urol. 2009;182(3):1055–1061. doi: 10.1016/j.juro.2009.05.045.
    1. Correia GN, Pereira VS, Hirakawa HS, Driusso P. Effects of surface and intravaginal electrical stimulation in the treatment of women with stress urinary incontinence: randomized controlled trial. Eur J Obstet Gynecol Reprod Biol. 2014;173:113–118. doi: 10.1016/j.ejogrb.2013.11.023.
    1. Schreiner L, dos Santos TG, Knorst MR, da Silva Filho IG. Randomized trial of transcutaneous tibial nerve stimulation to treat urge urinary incontinence in older women. Int Urogynecol J. 2010;21(9):1065–1070. doi: 10.1007/s00192-010-1165-6.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe